Artivion Q3 2026 Earnings: Revenue Rises as Profitability Weakens

Artivion (NYSE: AORT) reported Q3 2026 revenue of $123.8 million, up 9% from $113.4 million a year earlier, while diluted EPS swung to a loss of $0.16 from earnings of $0.13. On-X and aortic stent grafts drove revenue growth, but lower margins, higher expenses, and negative free cash flow defined the quarter.

Core Earnings Data

Revenue growth did not translate into higher earnings. Gross profit increased by only about $1.6 million, operating income fell sharply, and the company moved from a GAAP profit to a net loss.

The weakness was also visible on an adjusted basis: adjusted diluted EPS fell 50%, and adjusted EBITDA declined 8%. Quarterly operating cash flow and free cash flow both turned negative.

Non-GAAP net income was $3.8 million, down from $7.9 million. The Q3 2026 figure included $0.6 million of pretax foreign-currency revaluation losses.

Business and Segment Performance

Products generated all of the company’s quarterly revenue growth. Product revenue increased 12% to $98.2 million, while preservation services revenue was essentially unchanged at $25.6 million.

• Aortic stent grafts: Revenue reached $44.3 million, up 12% in constant currency. Management said this was the second consecutive quarter of 12% growth despite a more difficult prior-year comparison for AMDS.
• On-X: Revenue rose 13% in constant currency to $30.3 million, making it the fastest-growing major product category.
• Surgical sealants: Revenue was nearly flat at $18.9 million.
• Other products: Revenue increased 93% in constant currency to $4.6 million, although this remained a relatively small part of total sales.
• Preservation services: Revenue was flat in constant currency at $25.6 million.

Growth was positive across all reported regions. Constant-currency revenue increased 11% in Europe, the Middle East, and Africa; 8% in North America; 8% in Asia Pacific; and 5% in Latin America.

Revenue Growth Did Not Offset Cost and Expense Pressure

The main issue in Q3 was the gap between revenue growth and cost growth. Total cost of products and preservation services increased about 23%, substantially faster than the 9% increase in revenue. Product costs alone rose 28% while product revenue increased 12%, which compressed gross margin by about 4.2 percentage points.

Operating expenses then increased 12% to $73.0 million. General, administrative, and marketing expense rose to $63.2 million from $57.3 million, while research and development expense increased to $9.8 million from $8.1 million. The prior-year quarter also included a $3.5 million gain from the sale of non-financial assets that did not recur.

Below the operating line, interest expense rose to $8.5 million from $6.1 million. Business development, integration, and severance costs also increased to $5.8 million from $2.5 million. Although these costs are excluded from adjusted EBITDA, the decline in adjusted EBITDA shows that profitability pressure was not limited to GAAP adjustments.

Cash Flow and Balance Sheet

Quarterly operating cash flow was negative $4.6 million, compared with positive $22.3 million a year earlier. Capital expenditures increased to $13.0 million from $4.6 million, producing negative free cash flow of $17.6 million.

For the first nine months of 2026, operating cash flow was negative $4.7 million and capital expenditures were $31.8 million. Nine-month free cash flow was therefore negative $36.4 million, compared with positive $8.8 million in the first nine months of 2025.

Cash and cash equivalents declined to $48.4 million at September 30 from $64.9 million at the end of 2025. Inventories increased to $107.1 million from $92.4 million, while long-term debt rose to $363.8 million from $215.1 million. During the first nine months, Artivion used $116.7 million for the Endospan acquisition and received $148.9 million in net proceeds from new long-term debt.

2026 Guidance

Artivion narrowed both its revenue and adjusted EBITDA ranges without materially changing their midpoints. The tighter ranges reduce uncertainty around the company’s full-year expectations, but they do not signal a higher central outlook.

The outlook continues to assume that currency will provide an approximately one-percentage-point full-year tailwind. Adjusted EBITDA guidance also includes about $8 million of 2026 expenses associated with the Endospan acquisition, which closed in May. The adjusted 2025 revenue base used for the growth comparison excludes a $2.3 million reserve related to estimated repayments to the Italian government.

Management Commentary

Management said U.S. AMDS implants increased sequentially from Q2, which it attributed to the recent premarket approval and efforts to expand adoption. Preparations remain underway for the U.S. commercial launch of NEXUS in January 2027, with the first surgeon training event planned for December 2026.

The company also exited the quarter with an improved On-X supply position following investments in its Austin manufacturing facility. Enrollment in the ARTIZEN clinical trial for ARCEVO LSA remained on schedule. Management estimates that a comprehensive aortic arch portfolio could address an approximately $330 million annual U.S. market opportunity.

Recent Insider Transactions

The supplied six-month insider summary shows 112,459 shares purchased across 10 transactions and 135,792 shares sold across seven transactions, resulting in net sales of 23,333 shares. The latest 10 reported entries include seven sales, one derivative exercise or conversion, and two zero-price stock awards; this record alone does not establish insiders’ views on the company’s outlook.

All 10 transactions were reported as direct holdings.

Risks Investors Should Watch

• Margin recovery: Product costs increased much faster than product revenue, while adjusted EBITDA margin also declined. A continuation of this pattern would limit the earnings benefit from sales growth.
• Cash use and leverage: Negative free cash flow, higher capital spending, lower cash, and increased debt reduce financial flexibility. Rising inventory also ties up additional working capital.
• Endospan integration: The acquisition adds integration costs and debt. Artivion’s 2026 outlook includes approximately $8 million of related expenses, while the expected strategic benefits still depend on execution.
• Product launch and clinical execution: Future growth depends partly on AMDS adoption, the planned January 2027 NEXUS launch, surgeon training, and continued progress in the ARTIZEN trial.
• Foreign exchange: The full-year outlook assumes a currency tailwind, but Q3 adjusted net income still included a foreign-currency revaluation loss.

Conclusion

Artivion’s Q3 2026 revenue growth was led by On-X and aortic stent grafts, but higher product costs, operating expenses, interest expense, and capital spending weakened profitability and cash flow. The narrowed full-year guidance retains essentially unchanged midpoints, leaving margin recovery, cash generation, Endospan integration, and upcoming aortic-portfolio launches as the main areas to monitor.